UPDATE: Increase in FDA s Drug-Review Fee May Not Hurt Young Drug Developers | GenomeWeb

NEW YORK, Feb. 8 - A recent federal budget proposal to increase by 60 percent the US Food and Drug Administration's fee to review a new-drug application may not be that much of a headache for young drug developers, experts say. And if ultimately approved, the increase will represent only a tiny fraction of what it costs to bring a drug to market.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.